Overview

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study is to determine the safety and recommended dosing of Minnelide in Acute Myeloid Leukemia (AML)
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborator:
Minneamrita Therapeutics LLC
Treatments:
14-O-phosphonooxymethyltriptolide disodium salt